Seres Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q1 2014 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Seres Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2014 to Q3 2024.
  • Seres Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$29.2M, a 34.6% increase year-over-year.
  • Seres Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$142M, a 6.36% decline year-over-year.
  • Seres Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$108M, a 56.2% increase from 2022.
  • Seres Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$246M, a 282% decline from 2021.
  • Seres Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$64.5M, a 26.8% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$142M -$29.2M +$15.4M +34.6% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 -$158M -$31.3M -$80.9M -163% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 -$77M -$39.6M +$31M +43.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 -$108M -$42.4M +$26M +38% Oct 1, 2023 Dec 31, 2023 8-K 2024-08-15
Q3 2023 -$134M -$44.6M +$14.5M +24.6% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$148M $49.5M +$113M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 -$261M -$70.6M -$14.8M -26.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 -$246M -$68.3M -$18.9M -38.2% Oct 1, 2022 Dec 31, 2022 8-K 2024-08-15
Q3 2022 -$228M -$59.1M -$128M -186% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 -$100M -$63.3M -$15.2M -31.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$84.9M -$55.8M -$20.4M -57.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 -$64.5M -$49.4M -$31.5M -176% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-05
Q3 2021 -$33M $68.4M +$98.4M Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-02
Q2 2021 -$131M -$48.1M -$27.6M -134% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-03
Q1 2021 -$104M -$35.3M -$15.6M -79.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 -$88.1M -$17.9M +$1.29M +6.74% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-07
Q3 2020 -$89.4M -$30M -$12.8M -74.6% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$76.6M -$20.5M -$9.6M -87.7% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 -$67M -$19.7M +$4.86M +19.8% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-04
Q4 2019 -$71.9M -$19.2M +$2.48M +11.4% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-02
Q3 2019 -$74.4M -$17.2M +$5.03M +22.6% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 -$79.4M -$10.9M +$17.2M +61.1% Apr 1, 2019 Jun 30, 2019 10-Q 2020-07-28
Q1 2019 -$96.6M -$24.6M +$3.71M +13.1% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$100M -$21.7M +$8.1M +27.2% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-02
Q3 2018 -$108M -$22.2M -$14.9M -204% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-02
Q2 2018 -$93.5M -$28.1M +$280K +0.99% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-02
Q1 2018 -$93.8M -$28.3M -$2.38M -9.18% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-02
Q4 2017 -$91.4M -$29.8M -$4.09M -15.9% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-06
Q3 2017 -$87.3M -$7.31M +$11.8M +61.7% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-06
Q2 2017 -$99.1M -$28.4M -$276K -0.98% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-06
Q1 2017 -$98.8M -$25.9M -$5.97M -30% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-06
Q4 2016 -$92.8M -$25.7M -$5.9M -29.8% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-08
Q3 2016 -$86.9M -$19.1M -$4.53M -31.1% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-08
Q2 2016 -$82.4M -$28.1M -$15.8M -128% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-08
Q1 2016 -$66.6M -$19.9M -$11.7M -144% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-08
Q4 2015 -$54.9M -$19.8M -$12.6M -174% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-16
Q3 2015 -$42.3M -$14.6M -$11M -307% Jul 1, 2015 Sep 30, 2015 10-K 2017-03-16
Q2 2015 -$31.3M -$12.3M -$9.72M -371% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-16
Q1 2015 -$21.6M -$8.17M -$6.5M -388% Jan 1, 2015 Mar 31, 2015 10-K 2017-03-16
Q4 2014 -$15.1M -$7.21M Oct 1, 2014 Dec 31, 2014 10-K 2016-03-14
Q3 2014 -$3.58M Jul 1, 2014 Sep 30, 2014 10-K 2016-03-14
Q2 2014 -$2.62M Apr 1, 2014 Jun 30, 2014 10-K 2016-03-14
Q1 2014 -$1.67M Jan 1, 2014 Mar 31, 2014 10-K 2016-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.